Alpha-Ketoglutarate (AKG): Metabolic Longevity Support
AKG is a citric acid cycle intermediate that also acts as a cofactor for the enzymes that edit the epigenome. The mouse data are striking. The human data are almost entirely absent.
The Short Answer
Alpha-ketoglutarate is a metabolite at the centre of the citric acid cycle and a required cosubstrate for the dioxygenase enzymes that demethylate DNA and histones, which places it at the junction of energy metabolism and epigenetic regulation. Circulating concentrations decline substantially with age. In mice, calcium alpha-ketoglutarate given from middle age extended median lifespan modestly and compressed the period of frailty markedly, which is an unusual and desirable result profile. Human evidence consists of a small uncontrolled report from a commercial supplier plus trials in unrelated clinical contexts, so AKG sits firmly in the experimental category despite being sold as a longevity intervention.
Two Jobs in One Molecule
Energy metabolism. AKG sits in the citric acid cycle between isocitrate and succinyl-CoA. It is a node where carbon from carbohydrate, fat and amino acid metabolism converges, and it links to nitrogen handling through glutamate and glutamine, which is why it has a long history in clinical nutrition for nitrogen balance.
Epigenetic cofactor. This is the more interesting role. The TET enzymes that demethylate DNA and the JmjC-domain enzymes that demethylate histones are alpha-ketoglutarate-dependent dioxygenases: they require AKG as a cosubstrate and produce succinate. So AKG availability directly constrains the rate at which methylation marks can be removed.
That connection matters because epigenetic alteration is one of the hallmarks of aging and because the ratio of AKG to succinate acts as a metabolic signal read by the epigenome. A cell with abundant AKG has more demethylating capacity than one without. This is the mechanistic thread that makes a citric acid cycle intermediate a candidate longevity compound rather than merely a metabolite.
AKG also inhibits ATP synthase and the mTOR pathway in worm studies, which is the route by which its lifespan effect in that organism appears to operate, and it participates in collagen synthesis as a cofactor for prolyl hydroxylase, giving it a connective tissue role.
The Animal Evidence
Nematodes. AKG extended lifespan substantially, dependent on ATP synthase inhibition and downstream mTOR suppression.
Mice. The result that generated commercial interest: calcium alpha-ketoglutarate delivered in food from eighteen months of age extended median lifespan modestly, in the range of ten percent or so depending on sex, and produced a considerably larger effect on healthspan measures. Frailty scores, coat condition, gait, grip strength and activity were better maintained, and inflammatory cytokines were lower. The frailty compression was the striking part: the supplemented animals spent a much smaller fraction of their remaining life in a frail state.
That profile, modest lifespan extension with marked compression of late-life dysfunction, is arguably more relevant to human objectives than lifespan extension alone. It is also a single laboratory's result in one strain, and it has not been replicated in the multi-site programme that has tested other candidate compounds.
The Human Evidence, Stated Precisely
There is almost none for longevity purposes.
What exists. AKG and its salts have decades of use in clinical nutrition, in dialysis populations for nitrogen handling, in surgical recovery protocols, and in sports nutrition, with a reassuring safety record at gram-level doses. Ornithine alpha-ketoglutarate has been studied in wound healing and in catabolic states.
What is cited as longevity evidence. An uncontrolled observational report from the company selling a calcium AKG product described a reduction of several years in epigenetic age among users. There was no control group, no randomisation, self-selected participants, and a commercial interest in the outcome. It is not evidence of an effect; it is a reason to run a trial.
What does not exist. Any randomised controlled trial of AKG with functional, frailty, or aging-clock endpoints in humans. Anyone presenting AKG as demonstrated in people is describing a mouse study and a marketing document.
Forms, Dose and Practical Notes
- Calcium alpha-ketoglutarate. The form used in the mouse work and in most longevity-marketed products, typically 1,000 to 3,000 mg per day. Note that the calcium contributes to total calcium intake, which is worth counting for anyone already supplementing calcium.
- Arginine alpha-ketoglutarate. A sports nutrition staple, dosed in grams, with the arginine contributing its own effects. Not the form used in the longevity work.
- Ornithine alpha-ketoglutarate. Studied in clinical nutrition for nitrogen balance and wound healing, dosed in grams.
- Sustained-release preparations. AKG has a short plasma half-life, and the mouse study delivered it continuously in food, which is an argument for divided or sustained dosing rather than a single bolus. This is reasoning, not evidence.
Dietary AKG is not a meaningful route: it is an intracellular metabolite rather than a nutrient present in food at supplement-scale amounts. Endogenous production is the normal source, and it is production that declines with age.
Safety
AKG has a good safety record across its clinical nutrition history, and the mouse work ran long term without adverse findings. Reported effects at supplemental doses are gastrointestinal and mild.
Three practical points. The calcium load in calcium AKG counts toward total calcium intake and matters for anyone with a history of calcium-containing kidney stones or already taking calcium and vitamin D. AKG is metabolically active and the consequences of sustained supraphysiological concentrations in humans over years are unstudied. And because AKG participates in nitrogen handling, anyone with significant kidney or liver involvement should regard gram-level dosing as a clinical question.
How to Think About It
AKG is one of the more interesting compounds in the experimental category, for two reasons. The mechanism sits at a genuine junction between metabolism and the epigenome rather than being a peripheral antioxidant story. And the mouse result compressed frailty rather than merely stretching survival, which is the shape of outcome most people actually want.
Against that: one mouse study, no human trial, an uncontrolled sponsor report standing in for evidence, and a compound whose effects nobody can perceive. There is no readout. A member cannot tell whether it is working.
That combination argues for holding it at Evidence Level C, taking it only with a clear understanding that the rationale is mechanistic, and setting the review trigger externally: the publication of the first randomised human trial, or replication of the mouse result by an independent group. Neither has happened yet.
The AEONNN Perspective
AKG is exactly the kind of compound the Innovation layer exists to track. Its status will be decided by trials that are being designed and run now, not by anything a member can observe, which means the review trigger is external and belongs to the platform rather than to the person.
It maps to Cellular Energy and Repair through the citric acid cycle, to Structural and Musculoskeletal Support through collagen synthesis, and to the Longevity meta-Pillar through the frailty compression result. Insight Protocol labels it Level C, experimental and educational, and states plainly that the human evidence is an uncontrolled sponsor report rather than a trial.
The Quality layer adds a specific practical check that is easy to miss: calcium AKG contributes calcium, and a member already taking calcium and vitamin D is changing their total intake without noticing. That is the kind of cross-product arithmetic Stack Builder is built to catch.
Pillar Matrix mapping
Cellular Energy and Repair, Structural and Musculoskeletal Support, Longevity and Biological Age
Database Matrix layers
- Mechanistic Layer (KEGG, Reactome, UniProt)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Innovation Layer (bioRxiv preprints, patent filings)
- Safety Layer (DrugBank, FAERS)
- Quality / Formulation Layer (ConsumerLab, Labdoor)
Frequently Asked
Does AKG extend lifespan in humans?
Unknown. It extended median lifespan modestly in mice while markedly compressing frailty, and it extends lifespan in nematodes. No randomised human trial with aging endpoints exists.
How much AKG should be taken?
Products marketed for longevity typically supply 1,000 to 3,000 mg per day of calcium alpha-ketoglutarate. This range comes from scaling the mouse work rather than from human dose-finding.
What is the difference between calcium, arginine and ornithine AKG?
Calcium AKG is the form used in the mouse longevity work. Arginine AKG is a sports nutrition product whose arginine contributes its own effects. Ornithine AKG has clinical nutrition evidence for nitrogen balance and wound healing.
Why is AKG connected to epigenetics?
The TET enzymes that demethylate DNA and the JmjC enzymes that demethylate histones require alpha-ketoglutarate as a cosubstrate. AKG availability therefore constrains demethylating capacity, and the AKG to succinate ratio acts as a metabolic signal read by the epigenome.
Is the reported epigenetic age reduction from AKG real?
It comes from an uncontrolled observational report by the company selling the product, with self-selected participants and no control group. It is a reason to run a trial rather than evidence of an effect.
Can AKG be obtained from food?
Not meaningfully. It is an intracellular metabolite rather than a dietary nutrient present at supplement-scale amounts, and endogenous production is the normal source.
Who should be cautious with AKG?
Anyone with a history of calcium-containing kidney stones or already supplementing calcium, given the calcium load in calcium AKG, and anyone with significant kidney or liver involvement, given the role of AKG in nitrogen handling.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.